1. Adibhatla RM, Hatcher JF, Tureyen K. CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. Brain Res 2005; 1058: 193-197.
2.
Agulla J, Brea D, Campos F, Sobrino T, Argibay B, Al-Soufi W, Blanco M, Castillo J, Ramos-Cabrer P. In vivo theranostics at the peri-infarct region in cerebral ischemia. Theranostics 2013; 4: 90-105.
3.
Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci 1997; 9: 2734-2742.
4.
Aronowski J, Strong R, Grotta JC. Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. Neurol Res 1996; 18: 570-574.
5.
Choueiry J, Blais CM, Sha D, Smith D, Fisher D, Illivitsky V, Knott V. CDP-choline and galantamine, a personalized a7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study. Psychopharmacology (Berl) 2020; 237: 3665-3687.
6.
Council NR. Vitamin Tolerance of Animals. Washington, DC: The National Academies Press 1987.
7.
D’orlando KJ, Sandage BWJr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol Res 1995; 17: 281-284.
8.
Dorman RV, Dabrowiecki Z, Horrocks LA. Effects of CDPcholine and CDPethanolamine on the alterations in rat brain lipid metabolism induced by global ischemia. J Neurochem 1983; 40: 276-279.
9.
Ehlert FJ, Sawyer GW, Esqueda EE. Contractile role of M2 and M3 muscarinic receptors in gastrointestinal smooth muscle. Life Sci 1999; 64: 387-394.
10.
Fagone P, Jackowski S. Phosphatidylcholine and the CDP-choline cycle. Biochim Biophys Acta 2013; 1831: 523-532.
11.
Gad SC. Maximum Tolerated Dose, in Encyclopedia of Toxicology (Third Edition). Wexler P (ed.). Academic Press, Oxford 2014; p. 164.
12.
Galletti P, De Rosa M, Cotticelli MG, Morana A, Vaccaro R, Zappia V. Biochemical rationale for the use of CDPcholine in traumatic brain injury: pharmacokinetics of the orally administered drug. J Neurol Sci 1991; 103 Suppl.: S19-25.
13.
Galletti P, De Rosa M, Nappi MA, Pontoni G, Del Piano L, Salluzzo A, Zappia V. Transport and metabolism of double-labelled CDPcholine in mammalian tissues. Biochem Pharmacol 1985; 34: 4121-4130.
14.
Gibellini F, Smith TK. The Kennedy pathway – de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life 2010; 62: 414-428.
15.
Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs 2014; 28: 185-193.
16.
Grieb P, Jünemann A, Rekas M, Rejdak R. Citicoline: a food beneficial for patients suffering from or threated with glaucoma. Front Aging Neurosci 2016; 8: 73.
17.
Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B, Vallejo-
18.
Cremades MT, Alvarez-Grech J., Expósito-Alcaide M, Díez-Tejedor E. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int 2012; 60: 310-317.
19.
Hashihira S, Nishii T, Mori R, Takeda Y, Tai J. CDP-choline as a drug for pancreatitis. Bull Osaka Med Sch 1974; 20: 19-25.
20.
Horrocks LA, Dorman RV, Dabrowiecki Z, Goracci G, Porcellati G. CDPcholine and CDPethanolamine prevent the release of free fatty acids during brain ischemia. Prog Lipid Res 1981; 20: 531-534.
21.
Iino S, Nojyo Y. Muscarinic M(2) acetylcholine receptor distribution in the guinea-pig gastrointestinal tract. Neuroscience 2006; 138: 549-559.
22.
Kakihana M, Fukuda N, Suno M, Nagaoka A. Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia. Stroke 1988; 19: 217-222.
23.
Liu H, Jablonska A, Li Y, Cao S, Liu D, Chen H, Van Zijl PC, Bulte JW, Janowski M, Walczak P. Liu G. Label-free CEST MRI detection of citicoline-liposome drug delivery in ischemic stroke. Theranostics 2016; 6: 1588-1600.
24.
López-Coviella I, Agut J, Savci V, Ortiz JA, Wurtman RJ. Evidence that 5’-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. J Neurochem 1995; 65: 889-894.
25.
Martí-Carvajal AJ, Valli C, Martí-Amarista CE, Solà I, Martí-Fàbregas J, Bonfill Cosp X. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev 2020; 8: Cd013066.
26.
Martí Massó JF, Urtasun M. Citicoline in the treatment of Parkinson’s disease. Clin Ther 1991; 13: 239-242.
27.
Morris-Schaffer K, Mccoy MJ. A review of the LD50 and its current role in hazard communication. ACS Chem Health Saf 2021; 28: 25-33.
28.
Morton DB, Jennings M, Buckwell A, Ewbank R, Godfrey C, Holgate B, Inglis I, James R, Page C, Sharman I, Verschoyle R, Westall L, Wilson AB. Refining procedures for the administration of substances. Report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. British Veterinary Association Animal Welfare Foundation/Fund for the Replacement of Animals in Medical Experiments/Royal Society for the Prevention of Cruelty to Animals/Universities Federation for Animal Welfare. Lab Anim 2001; 35: 1-41.
29.
Paoletti X, Postel-Vinay S, Servois V, Doussau A, Ollivier L, Le Tourneau C. Dose finding methods for targeted agents: new perspectives. Bull Cancer 2010; 97: 1485-1495.
30.
Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5’-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999; 106: 1126-1134.
31.
Proctor GB. Muscarinic receptors and salivary secretion. J Appl Physiol (1985) 2006; 100: 1103-1104.
32.
Sai Latha S, Shivanna N, Naika M, Anilakumar KR, Kaul A, Mittal G.
33.
Toxic metabolite profiling of Inocybe virosa. Sci Rep 2020; 10: 13669.
34.
Sarkar AK, Ghosh D, Haldar D, Sarkar P, Gupta B, Dastidar SG, Pal TK. A rapid LC-ESI-MS/MS method for the quantitation of choline, an active metabolite of citicoline: Application to in vivo pharmacokinetic and bioequivalence study in Indian healthy male volunteers. J Pharm Biomed Anal 2012; 71: 144-147.
35.
Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis 2008; 5: 167-177.
36.
Schäbitz WR, Weber J, Takano K, Sandage BW, Locke KW, Fisher M. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci 1996; 138: 21-25.
37.
Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006; 28 Suppl. B: 1-56.
38.
Synoradzki K, Grieb P. Citicoline: a superior form of choline? Nutrients 2019; 11: 1569.
39.
Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, Kameyama M, Omae T, Fujishima M, Sakuma A. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988; 19: 211-216.
40.
Trovarelli G, De Medio GE, Dorman RV, Piccinin GL, Horrocks LA, Porcellati G. Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alterations of brain lipid in the gerbil. Neurochem Res 1981; 6: 821-833.
41.
Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol 2000; 60: 989-992.
